PE20080608A1 - Compuestos quimicos - Google Patents

Compuestos quimicos

Info

Publication number
PE20080608A1
PE20080608A1 PE2007001107A PE2007001107A PE20080608A1 PE 20080608 A1 PE20080608 A1 PE 20080608A1 PE 2007001107 A PE2007001107 A PE 2007001107A PE 2007001107 A PE2007001107 A PE 2007001107A PE 20080608 A1 PE20080608 A1 PE 20080608A1
Authority
PE
Peru
Prior art keywords
nitro
amino
methyl
halo
hydroxy
Prior art date
Application number
PE2007001107A
Other languages
English (en)
Inventor
Gregory Basarab
Pamela Hill
Kenneth Gregory Hull
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38705101&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080608(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20080608A1 publication Critical patent/PE20080608A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/113—Spiro-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES H, HALO, NITRO, ENTRE OTROS; R2 ES H, NITRO, HIDROXI, HALO, CIANO, ENTRE OTROS; R3 ES H, NITRO, HIDROXI, ALQUILO C1-C4, ENTRE OTROS; W ES -O-, -NR7, CR8R9; ANILLO A ES CARBOCICLICO, HETEROCICLILO, ENTRE OTROS; R4 Y R5 SON CADA UNO ES H, ALQUILO C1-C6, AZIDO, AMINO, ENTRE OTROS; R6 ES AZIDO, HALO, NITRO, CIANO, HIDROXI, TRIFLUOROMETOXI, AMINO, MERCAPTO, SULFAMOILO, ENTRE OTROS; m ES 0-4; R7, R8 Y R9 SON CADA UNO H, ALQUILO C1-C4. SON COMPUESTOS PREFERIDOS: 2-(10-{[(3,4-DICLORO-5-METIL-1H-PIRROL-2-IL)CARBONIL]AMINO}-1,4-DIOXA-7-AZASPIRO[4,5]DEC-7-IL)-1,3-TIAZOL-5-CARBOXILATO DE METILO; 4-ACETIL-2-(10-{[(3,4-DICLORO-5-METIL-1H-PIRROL-2-IL)CARBONIL]AMINO}-1,4-DIOXA-7-AZASPIRO[4,5]DEC-7-IL)-1,3-TIAZOL-5-CARBOXILATO DE METILO; ENTRE OTROS. REFERIDA TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDORES DE ADN GIRASA Y/O TOPOISOMERASA IV UTILES EN EL TRATAMIENTO DE INFECCIONES BACTERIANAS
PE2007001107A 2006-08-17 2007-08-16 Compuestos quimicos PE20080608A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82274706P 2006-08-17 2006-08-17
US82292306P 2006-08-18 2006-08-18
US89015107P 2007-02-15 2007-02-15

Publications (1)

Publication Number Publication Date
PE20080608A1 true PE20080608A1 (es) 2008-08-01

Family

ID=38705101

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001107A PE20080608A1 (es) 2006-08-17 2007-08-16 Compuestos quimicos

Country Status (9)

Country Link
US (1) US20100286181A1 (es)
EP (1) EP2064209A1 (es)
JP (1) JP2010500987A (es)
AR (1) AR063690A1 (es)
CL (1) CL2007002376A1 (es)
PE (1) PE20080608A1 (es)
TW (1) TW200819437A (es)
UY (1) UY30544A1 (es)
WO (1) WO2008020222A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006215399B2 (en) 2005-02-18 2010-12-09 Astrazeneca Ab Antibacterial piperidine derivatives
TW200906412A (en) * 2007-06-12 2009-02-16 Astrazeneca Ab Piperidine compounds and uses thereof
US20120108565A1 (en) * 2008-07-30 2012-05-03 Lalima Sharma Pyrrole carboxylic acid derivatives as antibacterial agents
JP2010209058A (ja) * 2008-09-29 2010-09-24 Sumitomo Chemical Co Ltd １−置換−トランス−４−（置換アミノ）ピペリジン−３−オールの製造方法
TW201026694A (en) * 2008-12-12 2010-07-16 Astrazeneca Ab Compound 468
TW201026695A (en) * 2008-12-12 2010-07-16 Astrazeneca Ab Piperidine compounds and uses thereof-596
TW201111380A (en) 2009-08-26 2011-04-01 Astrazeneca Ab Heterocyclic urea derivatives and methods of use thereof
KR20220013017A (ko) * 2014-01-06 2022-02-04 리젠 파마슈티컬스 소시에떼 아노님 신규한 글루타미나제 저해제
ES2817749T3 (es) * 2015-09-30 2021-04-08 Daiichi Sankyo Co Ltd Derivados de hidroxialquil tiadiazol
CA3056571C (en) 2017-03-14 2021-11-23 Daiichi Sankyo Company, Limited N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives
RU2019133662A (ru) 2017-03-24 2021-04-26 Тайсо Фармасьютикал Ко., Лтд. Производное 2(1h)-хинолинона
US20210323957A1 (en) 2018-09-03 2021-10-21 Univerza V Ljubljani New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria
CN111606827B (zh) * 2020-06-23 2022-10-25 内蒙古京东药业有限公司 一种制备依度沙班手性胺中间体的方法
WO2022129327A1 (en) 2020-12-17 2022-06-23 Univerza V Ljubljani New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200526626A (en) * 2003-09-13 2005-08-16 Astrazeneca Ab Chemical compounds
US8106048B2 (en) * 2004-09-20 2012-01-31 4Sc Ag Heterocyclic NF-κB inhibitors
AU2006215399B2 (en) * 2005-02-18 2010-12-09 Astrazeneca Ab Antibacterial piperidine derivatives

Also Published As

Publication number Publication date
UY30544A1 (es) 2008-03-31
AR063690A1 (es) 2009-02-11
US20100286181A1 (en) 2010-11-11
TW200819437A (en) 2008-05-01
EP2064209A1 (en) 2009-06-03
CL2007002376A1 (es) 2008-04-04
WO2008020222A1 (en) 2008-02-21
JP2010500987A (ja) 2010-01-14

Similar Documents

Publication Publication Date Title
PE20080608A1 (es) Compuestos quimicos
PE20070793A1 (es) Compuestos triciclicos que contienen nitrogeno como agentes antibacterianos
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20081583A1 (es) Agentes antibacterianos derivados de compuestos carbonilamino
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
PE20100053A1 (es) Compuestos heterociclicos como inhibidores de la adn girasa
PE20130647A1 (es) Indoles
PE20060691A1 (es) Serinamidas sustituidas por benzoilo
PE20080072A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20090276A1 (es) Compuestos derivados de imidazoquinolina como moduladores de tlr7
PE20120693A1 (es) Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
PE20120635A1 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas
PE20070814A1 (es) Compuestos derivados de 2-carboxitiofeno como inhibidores de la polimerasa del virus de la hepatitis c (hcv)
PE20070367A1 (es) Compuestos de espiropiperidina como inhibidores de la enzima beta secretasa
TW200745117A (en) Macrocylic inhibitors of hepatitis C virus
MX2007007428A (es) Compuestos heterociclicos, antagonistas de ccr2b.
GT200400092A (es) Preparacion y uso de derivados de alquilarilo para el tratamiento de la obesidad
PE20090511A1 (es) Imidazopiridinonas
PE20071177A1 (es) Derivados de 3,5-piridina como inhibidores de renina
BRPI0511610A (pt) derivados de amino-propanol
MY148566A (en) Crystalline solvates and complexes of (is) -1, 5- anhydro-1 -c-(3-( (phenyl) methyl) phenyl) -d-glucitol derivatives with amino acids as sglt2 inhibitors for the treatment of diabetes
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
AR057072A1 (es) Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto

Legal Events

Date Code Title Description
FD Application declared void or lapsed